Cyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement

Stock Information for Gevo Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Gevo Inc.

Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.